Symbols / AEMD Stock $2.20 -2.22% Aethlon Medical, Inc.

Healthcare • Medical Devices • United States • NCM
AEMD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. James B. Frakes M.B.A.
Exch · Country NCM · United States
Market Cap 3.45M
Enterprise Value -3.65M
Income -11.52M
Sales
FCF (ttm) -4.54M
Book/sh 6.90
Cash/sh 5.29
Employees 9
Insider 10d
IPO Mar 04, 1999
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E -2.24
PEG
P/S
P/B 0.32
P/C
EV/EBITDA 0.52
EV/Sales
Quick Ratio 5.53
Current Ratio 5.68
Debt/Eq 6.22
LT Debt/Eq
EPS (ttm) -48.46
EPS next Y -0.98
EPS Growth
Revenue Growth
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next) 2026-02-12
Earnings (prior) 2026-02-12
ROA -62.88%
ROE -208.60%
ROIC
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.57M
Shs Float 1.24M
Insider Own 7.51%
Instit Own 6.44%
Short Float 2.25%
Short Ratio 1.37
Short Interest 35.09K
52W High 35.20
vs 52W High -93.75%
52W Low 1.36
vs 52W Low 61.76%
Beta 1.52
Impl. Vol.
Rel Volume 0.17
Avg Volume 43.49K
Volume 7.38K
Target (mean) $4.75
Tgt Median $4.75
Tgt Low $1.50
Tgt High $8.00
# Analysts 2
Recom None
Prev Close $2.25
Price $2.20
Change -2.22%
About

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.20
Low
$1.50
High
$8.00
Mean
$4.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-14 reit HC Wainwright & Co. Neutral → Neutral $2
2025-03-10 reit HC Wainwright & Co. Buy → Buy $7
2025-02-19 reit HC Wainwright & Co. Buy → Buy $7
2025-01-30 reit HC Wainwright & Co. Buy → Buy $7
2024-11-15 reit HC Wainwright & Co. Buy → Buy $7
2024-06-24 main HC Wainwright & Co. Buy → Buy $7
2024-03-04 main HC Wainwright & Co. Buy → Buy $10
2023-10-24 main HC Wainwright & Co. Buy → Buy $23
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-17 BROENNIMAN EDWARD G Director 21,815 $2.29 $49,956
2026-04-17 ROSSETTI ANGELA Director 21,815 $2.29 $49,956
2026-04-17 SHAH CHETAN S Director 21,815 $2.29 $49,956
2026-04-17 GIKAKIS NICOLAS Director 21,815 $2.29 $49,956
2025-04-23 BROENNIMAN EDWARD G Director 142,857 $0.35 $50,000
2025-04-23 ROSSETTI ANGELA Director 142,857 $0.35 $50,000
2025-04-23 SHAH CHETAN S Director 142,857 $0.36 $51,143
2025-04-23 GIKAKIS NICOLAS Director 142,857 $0.35 $50,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
0.00
0.00
-100.00%
0.57
+95.21%
0.29
Operating Revenue
0.00
0.00
-100.00%
0.57
+95.21%
0.29
Operating Expense
9.34
-26.08%
12.64
+1.31%
12.47
+16.41%
10.72
Selling General And Administration
9.34
-26.08%
12.64
+1.31%
12.47
+16.41%
10.72
General And Administrative Expense
9.34
-26.08%
12.64
+1.31%
12.47
+16.41%
10.72
Salaries And Wages
3.87
-25.59%
5.21
+17.17%
4.44
-3.94%
4.63
Other Gand A
5.47
-26.42%
7.43
-7.46%
8.03
+31.86%
6.09
Total Expenses
9.34
-26.08%
12.64
+1.31%
12.47
+16.41%
10.72
Operating Income
-9.34
+26.08%
-12.64
-6.20%
-11.90
-14.18%
-10.42
Total Operating Income As Reported
-9.34
+26.08%
-12.64
-6.20%
-11.90
-14.18%
-10.42
EBITDA
-13.04
-6.20%
-12.28
-5.32%
-11.66
-13.21%
-10.30
Normalized EBITDA
-13.04
-6.20%
-12.28
-6.62%
-11.52
-11.83%
-10.30
Reconciled Depreciation
0.34
-5.43%
0.36
+49.05%
0.24
+94.76%
0.12
EBIT
-13.38
-5.87%
-12.64
-6.20%
-11.90
-14.18%
-10.42
Total Unusual Items
0.00
+100.00%
-0.14
0.00
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-0.14
0.00
Special Income Charges
0.00
+100.00%
-0.14
0.00
Net Income
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.49%
-10.42
Pretax Income
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.44%
-10.42
Net Non Operating Interest Income Expense
0.29
-35.62%
0.45
+3976.88%
0.01
0.00
Interest Expense Non Operating
0.01
Net Interest Income
0.29
-35.62%
0.45
+3976.88%
0.01
0.00
Interest Expense
0.01
Interest Income Non Operating
0.30
-33.36%
0.45
+3976.88%
0.01
0.00
Interest Income
0.30
-33.36%
0.45
+3976.88%
0.01
0.00
Other Income Expense
-4.33
-22760.13%
-0.02
+86.66%
-0.14
Other Non Operating Income Expenses
-4.33
-22760.13%
-0.02
Gain On Sale Of Business
0.00
+100.00%
-0.14
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.44%
-10.42
Net Income From Continuing Operation Net Minority Interest
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.49%
-10.42
Net Income From Continuing And Discontinued Operation
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.49%
-10.42
Net Income Continuous Operations
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.44%
-10.42
Minority Interests
0.00
-100.00%
0.00
Normalized Income
-13.39
-9.66%
-12.21
-2.70%
-11.89
-14.13%
-10.42
Net Income Common Stockholders
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.49%
-10.42
Diluted EPS
-8.58
+97.79%
-388.80
-723.73%
-47.20
+16.90%
-56.80
Basic EPS
-8.58
+97.79%
-388.80
-723.73%
-47.20
+16.90%
-56.80
Basic Average Shares
1.56
+396.93%
0.31
+22.35%
0.26
+39.17%
0.18
Diluted Average Shares
1.56
+396.93%
0.31
+22.35%
0.26
+39.17%
0.18
Diluted NI Availto Com Stockholders
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.49%
-10.42
Line Item Trend 2025-03-31 2024-03-31
Total Assets
7.36
-10.75%
8.25
Current Assets
5.95
-4.43%
6.23
Cash Cash Equivalents And Short Term Investments
5.50
+1.09%
5.44
Cash And Cash Equivalents
5.50
+1.09%
5.44
Cash Equivalents
5.16
+8.90%
4.74
Cash Financial
0.34
-51.33%
0.71
Receivables
Accounts Receivable
Prepaid Assets
Current Deferred Assets
0.00
-100.00%
0.28
Other Current Assets
0.45
-11.35%
0.51
Total Non Current Assets
1.41
-30.22%
2.02
Net PPE
1.28
-32.67%
1.90
Gross PPE
2.26
-21.87%
2.89
Accumulated Depreciation
-0.98
+1.18%
-0.99
Properties
0.00
0.00
Buildings And Improvements
Machinery Furniture Equipment
0.76
-31.52%
1.11
Other Properties
0.60
-31.84%
0.88
Leases
0.89
+0.00%
0.89
Goodwill And Other Intangible Assets
0.00
-50.00%
0.00
Other Intangible Assets
0.00
-50.00%
0.00
Non Current Prepaid Assets
0.03
+0.00%
0.03
Other Non Current Assets
0.10
+11.78%
0.09
Total Liabilities Net Minority Interest
2.24
-9.83%
2.48
Current Liabilities
1.90
+3.79%
1.83
Payables And Accrued Expenses
1.41
-8.53%
1.54
Payables
0.53
-31.28%
0.78
Accounts Payable
0.53
-31.28%
0.78
Current Accrued Expenses
0.87
+14.72%
0.76
Current Debt And Capital Lease Obligation
0.31
+7.73%
0.29
Current Capital Lease Obligation
0.31
+7.73%
0.29
Current Deferred Liabilities
Current Deferred Revenue
Total Non Current Liabilities Net Minority Interest
0.34
-48.18%
0.65
Long Term Debt And Capital Lease Obligation
0.34
-48.18%
0.65
Long Term Capital Lease Obligation
0.34
-48.18%
0.65
Stockholders Equity
5.12
-11.15%
5.77
Common Stock Equity
5.12
-11.15%
5.77
Capital Stock
0.00
+686.02%
0.00
Common Stock
0.00
+686.02%
0.00
Share Issued
2.59
+686.47%
0.33
Ordinary Shares Number
2.01
+511.70%
0.33
Treasury Shares Number
0.57
0.00
Additional Paid In Capital
173.09
+7.95%
160.34
Retained Earnings
-167.95
-8.66%
-154.57
Gains Losses Not Affecting Retained Earnings
-0.02
-146.87%
-0.01
Minority Interest
Other Equity Adjustments
-0.02
-146.87%
-0.01
Total Equity Gross Minority Interest
5.12
-11.15%
5.77
Total Capitalization
5.12
-11.15%
5.77
Working Capital
4.05
-7.86%
4.40
Invested Capital
5.12
-11.15%
5.77
Total Debt
0.65
-30.90%
0.94
Capital Lease Obligations
0.65
-30.90%
0.94
Net Tangible Assets
5.12
-11.14%
5.77
Tangible Book Value
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-7.65
+24.52%
-10.13
+3.57%
-10.51
-7.56%
-9.77
Cash Flow From Continuing Operating Activities
-7.65
+24.52%
-10.13
+3.57%
-10.51
-7.56%
-9.77
Net Income From Continuing Operations
-13.39
-9.66%
-12.21
-1.48%
-12.03
-15.44%
-10.42
Depreciation Amortization Depletion
0.34
-5.43%
0.36
+49.05%
0.24
+94.76%
0.12
Depreciation
0.34
-5.44%
0.36
+49.17%
0.24
Amortization Cash Flow
0.00
+0.00%
0.00
+0.00%
0.00
Depreciation And Amortization
0.34
-5.43%
0.36
+49.05%
0.24
+94.76%
0.12
Amortization Of Intangibles
0.00
+0.00%
0.00
+0.00%
0.00
Other Non Cash Items
4.89
+3422326.57%
0.00
-99.41%
0.02
-20.06%
0.03
Stock Based Compensation
0.42
-65.95%
1.22
+15.92%
1.05
+40.14%
0.75
Operating Gains Losses
0.02
-85.13%
0.14
Gain Loss On Sale Of PPE
0.00
-100.00%
0.02
0.00
Change In Working Capital
0.09
-80.43%
0.48
+632.58%
0.07
+126.02%
-0.25
Change In Receivables
0.00
-100.00%
0.13
+505.98%
0.02
Changes In Account Receivables
0.00
-100.00%
0.13
+505.98%
0.02
Change In Prepaid Assets
0.11
+1213.40%
-0.01
-102.57%
0.40
+162.54%
-0.64
Change In Payables And Accrued Expense
-0.02
-104.14%
0.49
+520.56%
-0.12
-186.26%
0.13
Change In Payable
-0.02
-104.14%
0.49
+520.56%
-0.12
-186.26%
0.13
Change In Account Payable
-0.05
-134.06%
0.16
+189.67%
-0.17
-279.13%
0.10
Change In Other Working Capital
-0.34
-250.00%
0.23
Investing Cash Flow
0.00
+100.00%
-0.25
+73.40%
-0.94
-170.08%
-0.35
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.25
+73.40%
-0.94
-170.08%
-0.35
Net PPE Purchase And Sale
0.00
+100.00%
-0.25
+73.40%
-0.94
-170.08%
-0.35
Purchase Of PPE
0.00
+100.00%
-0.25
+73.40%
-0.94
-170.08%
-0.35
Capital Expenditure
-0.25
+73.40%
-0.94
-170.08%
-0.35
Gain Loss On Sale Of Business
0.00
-100.00%
0.14
0.00
Financing Cash Flow
7.73
+500.14%
1.29
-85.56%
8.91
-48.67%
17.37
Cash Flow From Continuing Financing Activities
7.73
+500.14%
1.29
-85.56%
8.91
-48.67%
17.37
Net Common Stock Issuance
3.54
+167.69%
1.32
-85.19%
8.93
-48.86%
17.46
Proceeds From Stock Option Exercised
4.37
0.00
Net Other Financing Charges
-0.18
-428.45%
-0.03
-178.38%
-0.01
+85.82%
-0.09
Changes In Cash
0.08
+100.90%
-9.09
-258.91%
-2.53
-134.94%
7.25
Effect Of Exchange Rate Changes
-0.01
-681.96%
0.00
+135.37%
-0.01
Beginning Cash Position
5.53
-62.18%
14.62
-14.80%
17.16
+73.19%
9.91
End Cash Position
5.60
+1.26%
5.53
-62.18%
14.62
-14.80%
17.16
Free Cash Flow
-7.65
+26.35%
-10.38
+9.33%
-11.45
-13.17%
-10.12
Common Stock Issuance
3.54
+167.69%
1.32
-85.19%
8.93
-48.86%
17.46
Issuance Of Capital Stock
3.54
+167.69%
1.32
-85.19%
8.93
-48.86%
17.46
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category